← Leaderboards
Barney Graham
National Institute Of Allergy And Infectious Diseases
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Institute Of Allergy And Infectious Diseases
Same institution · by research overlap
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesImmune ResponseImmunizationBaseVaccine DevelopmentImmunogenicityDesignVirusAntigensInfectionResponseVaccine CandidateT Cell ResponseNeutralizing AntibodyGlycoproteinsCd8b1 GeneEpitopesAntibodiesStructureProteinsAdultVaccinationRespiratory Syncytial Virus InfectionsMediating
Grant awards (81)
Rapid Development of Vaccines for Emerging Viruses$1,604,857
ZIA · FY2021 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$1,447,312
ZIA · FY2021 · AI · contact PI
Cellular Immune Responses to RSV infection in Mice$728,613
ZIA · FY2021 · AI · contact PI
Coronavirus vaccine development$522,460
ZIA · FY2021 · AI · contact PI
Influenza Vaccine Development$3,038,369
ZIA · FY2020 · AI · contact PI
Coronavirus vaccine development$1,394,275
ZIA · FY2020 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$1,309,145
ZIA · FY2020 · AI · contact PI
Rapid Development of Vaccines for Emerging Viruses$1,309,145
ZIA · FY2020 · AI · contact PI
Cellular Immune Responses to RSV infection in Mice$654,025
ZIA · FY2020 · AI · contact PI
Influenza Vaccine Development$3,806,087
ZIA · FY2019 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$1,903,044
ZIA · FY2019 · AI · contact PI
Rapid Development of Vaccines for Emerging Viruses$1,903,044
ZIA · FY2019 · AI · contact PI
Coronavirus vaccine development$951,522
ZIA · FY2019 · AI · contact PI
Cellular Immune Responses to RSV infection in Mice$951,522
ZIA · FY2019 · AI · contact PI
Influenza Vaccine Development$2,042,985
ZIA · FY2018 · AI · contact PI
Rapid Development of Vaccines for Emerging Viruses$2,000,768
ZIA · FY2018 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$871,866
ZIA · FY2018 · AI · contact PI
Cellular Immune Responses to RSV infection in Mice$735,184
ZIA · FY2018 · AI · contact PI
Coronavirus vaccine development$435,933
ZIA · FY2018 · AI · contact PI
Influenza Vaccine Development$2,378,449
ZIA · FY2017 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$1,113,346
ZIA · FY2017 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$1,061,274
ZIA · FY2017 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$840,954
ZIA · FY2017 · AI · contact PI
Coronavirus vaccine development$840,953
ZIA · FY2017 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$718,377
ZIA · FY2017 · AI · contact PI
Rapid Development of a Vaccine for Zika Virus$122,576
ZIA · FY2017 · AI · contact PI
Rapid Development of a Vaccine for Zika Virus$39,678,048
ZIA · FY2016 · AI · contact PI
Influenza Vaccine Development$1,402,202
ZIA · FY2016 · AI · contact PI
Antigenicity and Immunogenicity of Stabilized prefusion F protein$1,232,506
ZIA · FY2016 · AI · contact PI
Coronavirus vaccine development$968,136
ZIA · FY2016 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$953,316
ZIA · FY2016 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$745,542
ZIA · FY2016 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$516,116
ZIA · FY2016 · AI · contact PI
Influenza Vaccine Development$1,402,202
ZIA · FY2015 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$1,097,964
ZIA · FY2015 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$545,542
ZIA · FY2015 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$503,316
ZIA · FY2015 · AI · contact PI
Coronavirus vaccine development$268,136
ZIA · FY2015 · AI · contact PI
Influenza Vaccine Development$1,402,202
ZIA · FY2014 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$1,109,300
ZIA · FY2014 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$545,542
ZIA · FY2014 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$503,316
ZIA · FY2014 · AI · contact PI
Coronavirus vaccine development$378,381
ZIA · FY2014 · AI · contact PI
HIV Preventive Vaccine and Monoclonal Antibody Studies$5,562,116
ZIA · FY2013 · AI · contact PI
Influenza Vaccine Development$1,695,001
ZIA · FY2013 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$1,353,692
ZIA · FY2013 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$851,944
ZIA · FY2013 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$645,542
ZIA · FY2013 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$613,074
ZIA · FY2013 · AI · contact PI
Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects$531,136
ZIA · FY2013 · AI · contact PI
Sample Collection and General Screening Protocols$509,733
ZIA · FY2013 · AI · contact PI
HIV Preventive Vaccine Studies$5,562,116
ZIA · FY2012 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$1,420,303
ZIA · FY2012 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$851,944
ZIA · FY2012 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$686,747
ZIA · FY2012 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$618,781
ZIA · FY2012 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$531,136
ZIA · FY2012 · AI · contact PI
Sample Collection and General Screening Protocols$509,733
ZIA · FY2012 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$4,251,944
ZIA · FY2011 · AI · contact PI
HIV Preventive Vaccine Studies$3,952,801
ZIA · FY2011 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$1,275,378
ZIA · FY2011 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$770,191
ZIA · FY2011 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$623,617
ZIA · FY2011 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$531,136
ZIA · FY2011 · AI · contact PI
Sample Collection and General Screening Protocols$509,733
ZIA · FY2011 · AI · contact PI
ARRA: Clinical Support for Universal Influenza Development$8,654,779
ZIA · FY2010 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$4,251,944
ZIA · FY2010 · AI · contact PI
HIV Preventive Vaccine Studies$4,122,073
ZIA · FY2010 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$940,148
ZIA · FY2010 · AI · contact PI
Sample Collection Protocols$555,292
ZIA · FY2010 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$555,292
ZIA · FY2010 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$443,301
ZIA · FY2010 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$275,320
ZIA · FY2010 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$2,370,253
ZIA · FY2009 · AI · contact PI
HIV Preventive Vaccine Studies$1,785,677
ZIA · FY2009 · AI · contact PI
Sample Collection Protocols$1,050,000
ZIA · FY2009 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$1,006,825
ZIA · FY2009 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$1,006,825
ZIA · FY2009 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$267,288
ZIA · FY2009 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$267,288
ZIA · FY2009 · AI · contact PI
Clinical Trial Infrastructure Support - Data/Enrollee Management$2,304,917
Z01 · FY2008 · AI · contact PI